
ReproCELL Incorporated — Investor Relations & Filings
ReproCELL Incorporated is a global company providing solutions for preclinical and clinical research, with a primary focus on stem cell technology, drug discovery, and regenerative medicine. The company's portfolio includes a wide range of products such as induced pluripotent stem cells (iPSCs), differentiated cells, 3D cell culture models, and specialized reagents like RNA-based reprogramming kits that avoid genomic integration. ReproCELL also offers extensive contract research services, including human tissue assays for evaluating drug efficacy and safety. A key area of expertise is the GMP-compliant manufacturing of clinical-grade iPSCs and iPSC-derived mesenchymal stem cells (iMSCs), supporting the development of advanced cell therapies. The company's tools and services are designed to help academic and commercial scientists accelerate the translation of research into clinical applications.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 連結子会社(REPROCELL USA Inc.)に対する補助金の交付決定に関するお知らせ | 2026-05-22 | Japanese | |
| 確認書 | 2025-11-13 | Japanese | |
| 半期報告書-第24期(2025/04/01-2026/03/31) | 2025-11-13 | Japanese | |
| 内部統制報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese | |
| 確認書 | 2025-06-26 | Japanese | |
| 有価証券報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese |
Browse filings by year
12 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
1 filing
| |||||
| 46779402 | 連結子会社(REPROCELL USA Inc.)に対する補助金の交付決定に関するお知らせ | 2026-05-22 | Japanese | ||
|
2025
5 filings
| |||||
| 8284113 | 確認書 | 2025-11-13 | Japanese | ||
| 8284101 | 半期報告書-第24期(2025/04/01-2026/03/31) | 2025-11-13 | Japanese | ||
| 7246941 | 内部統制報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese | ||
| 7246936 | 確認書 | 2025-06-26 | Japanese | ||
| 7246939 | 有価証券報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese | ||
|
2024
9 filings
| |||||
| 7298959 | 確認書 | 2024-11-13 | Japanese | ||
| 7298954 | 半期報告書-第23期(2024/04/01-2025/03/31) | 2024-11-13 | Japanese | ||
| 7325542 | 臨時報告書 | 2024-06-26 | Japanese | ||
| 7328563 | 内部統制報告書-第22期(2023/04/01-2024/03/31) | 2024-06-25 | Japanese | ||
| 7328560 | 確認書 | 2024-06-25 | Japanese | ||
| 7328561 | 有価証券報告書-第22期(2023/04/01-2024/03/31) | 2024-06-25 | Japanese | ||
| 7336087 | 臨時報告書 | 2024-05-23 | Japanese | ||
| 7356961 | 確認書 | 2024-02-09 | Japanese | ||
| 7356958 | 四半期報告書-第22期第3四半期(2023/10/01-2023/12/31) | 2024-02-09 | Japanese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Annovis Bio, Inc.
A clinical-stage drug platform company developing therapies…
|
ANVS | US | Professional, scientific and te… |
|
AnorMED Inc.
Developed small molecule therapeutics for serious diseases,…
|
— | CA | Professional, scientific and te… |
|
ANTEOTECH LTD
Develops nanoglue technology for life sciences and lithium-…
|
ADO | AU | Professional, scientific and te… |
|
Anthem Biosciences Limited
Integrated CRAMS organization for drug discovery, developme…
|
ANTHEM | IN | Professional, scientific and te… |
|
APPLIED DNA SCIENCES INC
Develops and manufactures DNA-based technologies for geneti…
|
APDN | US | Professional, scientific and te… |
|
Aprea Therapeutics, Inc.
Clinical-stage biopharma developing cancer therapeutics via…
|
APRE | US | Professional, scientific and te… |
|
AprilBio Co.,Ltd.
Develops long-acting biologic drugs for autoimmune diseases…
|
397030 | KR | Professional, scientific and te… |
|
Aptahem AB
A clinical-stage biotech developing aptamer-based drugs for…
|
APTA | SE | Professional, scientific and te… |
|
APTAMER GROUP PLC
Develops custom affinity binders for research, diagnostics,…
|
APTA | GB | Professional, scientific and te… |
|
Aptevo Therapeutics Inc.
Clinical-stage biotech developing antibody-based immunother…
|
APVO | US | Professional, scientific and te… |
ReproCELL Incorporated via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/13724/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=13724 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=13724 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=13724 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 13724}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ReproCELL Incorporated (id: 13724)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.